Overall The University of Arizona Cancer Center (UACC) in Tucson, Arizona has been an NCI-designated Cancer Center since 1978 and a Comprehensive Cancer Center since 1990. It was founded as a matrix center within the University of Arizona (UA), and its members represent 43 Colleges and 11 Departments. In 2014, the UACC was elevated to a status equivalent to that of a College, reporting directly to the Senior Vice President of Health Sciences. At this time, Andrew S. Kraft, MD, was appointed Director of the UACC. With authority for all cancer-related activities at the UA, he is spearheading the utilization of the significant Institutional support to enhance the Program. This includes the recently completed $100M 220,000 square foot outpatient clinic in Phoenix, which will greatly enhance translational research, an expansion of basic research space with occupancy of 20,000 square feet within two years, and an Institutional Commitment of $232M dollars over the next five years. The functionality of the Center has been enhanced by optimization of the Administration and Senior Leadership infrastructure. The UACC Strategic Plan for 2015?2020 calls for the continuation of the highly innovative and impactful team science based on four robust cornerstone Programs: Cancer Biology, Cancer Imaging, Therapeutic Development, and Cancer Prevention and Control. Strategic recruitment and pilot funding is focused on team building, including development of inter-programmatic collaborations and movement of research into the clinic. The UACC will continue to invest in its eight integrated Shared Resources that enhance the capabilities of UACC investigators in basic, prevention, translational, and clinical research, and another in development. The Clinical Trials Office has been strengthened, and investments supporting precision medicine initiatives are ongoing. The UACC is the only major academic Cancer Center in a 400 square mile area of driving distance and is committed to serving the residents in this region and its direct catchment area of southern Arizona. Thus, it has a focus on skin cancer and arsenic exposure as well as the needs of Hispanics, Native Americans, the elderly, and the economically disadvantaged. It has established a robust infrastructure of international, national, and regional collaborations and outreach programs together with research spanning epidemiology, genetics, epigenetics, cell biology, and signaling mechanisms, as well as targeted interventions and understudied survivorship issues. To capture the emerging synergies, the positions of Associate Director of Cancer Disparities and Associate Director of Precision Medicine and Bioinformatics have been created and filled by nationally recognized experts. The UACC emphasis on inclusive training of the next generation of cancer researchers has had demonstrable success in graduation of Native American and Latinos. The research generated by UACC members is characterized by its impact, its relevance to the catchment area, and its innovation. The Strategic Plan builds on the work that has resulted in 1,756 cancer- related publications in the reporting period and its current portfolio of $44M in peer-reviewed support.

Public Health Relevance

The University of Arizona Cancer Center (UACC) in Tucson, Arizona has been an NCI-designated Cancer Center since 1978 and a Comprehensive Cancer Center since 1990. Its four major research areas fall into the following organized scientific programs: Cancer Biology, Cancer Imaging, Therapeutic Development, and Cancer Prevention and Control. UACC has a research focus on skin cancer and arsenic exposure, as well as the cancer health needs of Hispanics and Native Americans, the elderly, and the economically disadvantaged.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA023074-36
Application #
9149082
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-07-01
Project End
2021-06-30
Budget Start
2016-07-14
Budget End
2017-06-30
Support Year
36
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Arizona
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Tao, Shasha; Rojo de la Vega, Montserrat; Chapman, Eli et al. (2018) The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Mol Carcinog 57:182-192
Goldenberg, Joshua M; Pagel, Mark D; Cárdenas-Rodríguez, Julio (2018) Characterization of D-maltose as a T2 -exchange contrast agent for dynamic contrast-enhanced MRI. Magn Reson Med 80:1158-1164
Blohm-Mangone, Karen; Burkett, Nichole B; Tahsin, Shekha et al. (2018) Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila) 11:265-278
Russ, Atlantis; Hua, Anh B; Montfort, William R et al. (2018) Blocking ""don't eat me"" signal of CD47-SIRP? in hematological malignancies, an in-depth review. Blood Rev 32:480-489
Bell, Melanie L; Whitehead, Amy L; Julious, Steven A (2018) Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes. Clin Epidemiol 10:153-157
Kannaiyan, Radhamani; Mahadevan, Daruka (2018) A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther 18:1249-1270
Berghout, Joanne; Li, Qike; Pouladi, Nima et al. (2018) Single subject transcriptome analysis to identify functionally signed gene set or pathway activity. Pac Symp Biocomput 23:400-411
Xie, Shuwei; Reinecke, James B; Farmer, Trey et al. (2018) Vesicular trafficking plays a role in centriole disengagement and duplication. Mol Biol Cell 29:2622-2631
Weinkauf, Craig C; Concha-Moore, Kirsten; Lindner, Jonathan R et al. (2018) Endothelial vascular cell adhesion molecule 1 is a marker for high-risk carotid plaques and target for ultrasound molecular imaging. J Vasc Surg 68:105S-113S
Song, Jin H; Singh, Neha; Luevano, Libia A et al. (2018) Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther 17:2710-2721

Showing the most recent 10 out of 1336 publications